Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.41 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080323 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL20161660 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL20161682 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL28909060 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL20265963 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL17080339 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL20265967 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL17080340 | 1.00 | PYGB (0.44) | PYGBGAALGALS1LGALS3LGALS9 | |
| SCHEMBL21342377 | 0.84 | LGALS3 (0.49) | LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL20161936 | 0.84 | LGALS3 (0.49) | LGALS1LGALS3LGALS9LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364189-B2 | Method for the treatment of keratin materials using amide C-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2022-06-21 | — | — | US | disclosed |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20190274940-A1 | METHOD FOR THE TREATMENT OF KERATIN MATERIALS USING AMIDE C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2019-09-12 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | PYGB 3409/4885GAA 271/4885LGALS1 408/4885 |
| US-11364189-B2 | Method for the treatment of keratin materials using amide C-glycoside derivatives, and cosmetic composition containing same | KRT18, KRTCAP2, F12 | PYGB 3948/4885GAA 703/4885LGALS1 373/4885 |
| US-20190274940-A1 | METHOD FOR THE TREATMENT OF KERATIN MATERIALS USING AMIDE C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, KRTCAP2, F12 | PYGB 3948/4885GAA 703/4885LGALS1 373/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | PYGB 3409/4885GAA 271/4885LGALS1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.